BC Week In Review | Jun 2, 2017
Clinical News

CASI completes enrollment in Phase II of ENMD-2076 for TNBC

In April, CASI Pharmaceuticals Inc. (NASDAQ:CASI) completed enrollment of 41 patients in a Phase II trial of ENMD-2076 in previously treated patients with locally advanced or metastatic triple-negative breast cancer (TNBC). The open-label, U.S. trial...
BC Week In Review | Jun 2, 2017
Clinical News

CASI reports Phase II data for ENMD-2076 in clear cell ovarian cancer

In an abstract released ahead of the American Society of Clinical Oncology meeting in Chicago, CASI Pharmaceuticals Inc. (NASDAQ:CASI) reported data from 37 evaluable patients with recurrent clear cell ovarian cancer in a Phase II...
BC Innovations | Oct 27, 2016
Translation in Brief

Blueprint for fusion

Blueprint Medicines Corp. (NASDAQ:BPMC) and researchers at The Rockefeller University are ramping up their collaboration to develop inhibitors of a disease-driving fusion protein found in all patients with fibrolamellar carcinoma, a rare subtype of hepatocellular...
BC Week In Review | Sep 5, 2016
Clinical News

ENMD-2076: Interim Phase II data

Data from 16 patients with locally advanced or metastatic fibrolamellar carcinoma in stage 1 of a 2-stage, open-label, U.S. Phase II trial showed that once-daily 250 mg oral ENMD-2076 met the stage 1 endpoint of...
BC Week In Review | Nov 23, 2015
Clinical News

ENMD-2076: Phase II started

CASI began an open-label, U.S. Phase II trial to evaluate 250 mg oral ENMD-2076 once daily in 28-day cycles in about 29 patients. CASI Pharmaceuticals Inc. (NASDAQ:CASI), Rockville, Md.   Product: ENMD-2076   Business: Cancer...
BC Week In Review | Aug 18, 2014
Clinical News

ENMD-2076: Phase II data

Researchers at Princess Margaret Cancer Centre reported data from 11 evaluable patients with advanced or metastatic STS in the open-label, single-arm, Canadian Phase II Study 2076-STS-001 showing that once-daily oral ENMD-2076 led to a CBR...
BC Week In Review | Jul 28, 2014
Clinical News

ENMD-2076 regulatory update

CASI (formerly EntreMed Inc. ) said FDA granted Orphan Drug designation to ENMD-2076 to treat hepatocellular carcinoma (HCC). The inhibitor of aurora kinase A ( AURKA ; Aurora-A ) and multiple tyrosine kinases is in Phase II testing...
BC Innovations | Aug 8, 2013
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer Aurora kinase A (AURKA; Aurora-A); AURKB (Aurora-B) In vitro and mouse studies suggest furanopyrimidine-based dual AURKA and AURKB inhibitors could help treat cancer....
BC Week In Review | Aug 5, 2013
Clinical News

ENMD-2076: Phase I started

EntreMed began a single-blind, dose-escalation, crossover, U.S. Phase I trial to evaluate 2 doses of ENMD-2076 in about 29 healthy volunteers. The study includes a food effect arm and is expected to satisfy FDA's requirement...
BioCentury | Mar 11, 2013
Regulation

Dissecting Kadcyla

Two and a half years after FDA refused to file Genentech Inc. 's BLA for accelerated approval of Kadcyla ado-trastuzumab emtansine in metastatic breast cancer, the agency has granted full approval - and outlined its rationale...
Items per page:
1 - 10 of 40